Cannabidiolic acid (CBDA), a minor non-psychoactive cannabinoid, has demonstrated greater neuroprotective effects than riluzole—the only widely approved ALS (amyotrophic lateral sclerosis) treatment—in a new study involving an aninal model of ALS.
(Photo credit: EcoLink).
Published in Biomedicine & Pharmacotherapy, the research evaluated CBDA alongside four other cannabinoids and found it to be the most effective in preserving motor neurons and reducing neuroinflammation.
Researchers administered CBDA daily from early symptoms to advanced stages in TDP-43 transgenic mice, which model key features of ALS. At a dose of 10 mg/kg, CBDA improved motor coordination, reduced spinal cord gliosis, and decreased levels of proinflammatory cytokines like IL-1β and TNF-α. Flow cytometry confirmed that CBDA shifted microglial cells from a proinflammatory (M1) to an anti-inflammatory (M2) state—an effect mirrored in BV2 microglial cell cultures.
A dose-response trial showed that only the 10 mg/kg dose was both effective and safe. Lower doses produced limited benefits, while a 100 mg/kg dose was toxic. Comparisons with riluzole revealed that CBDA outperformed the drug on multiple metrics, including motor neuron preservation and inflammation markers. Notably, combining CBDA with riluzole reduced the cannabinoid’s benefits, indicating a possible antagonistic interaction.
The study concludes that CBDA has a distinct and potent neuroprotective profile not attributable to conversion into CBD, with mechanisms likely involving non-cannabinoid receptors such as PPARs and TRPV1. Authors recommend further preclinical work in additional ALS models and pharmacokinetic studies to support potential clinical trials. Given the lack of effective ALS therapies, CBDA may represent a promising new avenue for treatment development.
More articles from The Marijuana Herald:
